Evolus (NASDAQ:EOLS) Price Target Raised to $25.00

Evolus (NASDAQ:EOLS) had its price objective hoisted by stock analysts at Barclays from $22.00 to $25.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 85.19% from the company’s previous close.

EOLS has been the subject of several other research reports. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Tuesday, January 21st. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Friday, February 14th.

Evolus Stock Performance

Evolus stock opened at $13.50 on Wednesday. Evolus has a 12-month low of $9.25 and a 12-month high of $17.82. The company has a market capitalization of $854.83 million, a price-to-earnings ratio of -14.84 and a beta of 1.33. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The firm’s fifty day moving average price is $12.85 and its 200 day moving average price is $14.08.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Jefferies Financial Group Inc. acquired a new position in shares of Evolus in the 4th quarter valued at about $753,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Evolus by 6.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,052 shares of the company’s stock valued at $1,270,000 after purchasing an additional 6,821 shares during the period. Zimmer Partners LP boosted its stake in Evolus by 66.6% during the 4th quarter. Zimmer Partners LP now owns 416,500 shares of the company’s stock valued at $4,598,000 after purchasing an additional 166,500 shares during the period. Tang Capital Management LLC boosted its stake in Evolus by 3.1% during the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock valued at $55,171,000 after purchasing an additional 150,000 shares during the period. Finally, Rafferty Asset Management LLC acquired a new position in Evolus during the 4th quarter valued at about $115,000. 90.69% of the stock is owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.